SeeTreat receives CUREator+ grant
We are proud to be part of eight Australian startups developing innovations with the potential to save lives and improve wellbeing receiving grants totalling $18.5 million thanks to the first CUREator+ funding round 🎉
Delivered in partnership with Brandon BioCatalyst (Brandon Capital) and ANDHealth, CUREator+ is a national program focused on accelerating the research translation and commercialisation of preclinical and clinical early-stage Australian medical research and medical innovations with commercial potential.
These innovations include drugs (novel and repurposed), devices, diagnostics and digital technologies that address unmet needs.
The first-round recipients are:
- ⭐️ Amplificare: Enabling rapid assessment of the efficacy of cancer treatments
- ⭐️ Baymatob: AI-powered platform providing early warning for treatable pregnancy and labour complications
- ⭐️ Currus Biologics Pty Ltd: Technology to develop CAR T-cell Therapy in tumours
- ⭐️ Kinoxis Therapeutics Pty Ltd: An alternative to antipsychotics for managing agitation and aggression in dementia
- ⭐️ Micromune Therapeutics: A therapy for treating inflammatory bowel disease
- ⭐️ Mirugen: Utilising gene therapy to restore vision in patients with 'incurable' blindness
- ⭐️ OncoRes Medical: Imaging technology which differentiates cancer from healthy tissue
- ⭐️ SeeTreat Medical: Software to improve the accuracy and effectiveness of radiation therapy for breast cancer
The Hon Mark Butler MP, Minister for Health and Aged Care, said, “Turning new research into medicines and tools which can be used to treat patients is often a long and costly process. Our support will ensure innovative research can become life changing and lifesaving treatments.”
ANDHealth CEO Bronwyn Le Grice said, “In the current market, substantive equity-free funding such as provided under CUREator+ and access to global industry leaders with proven track records, can make a material difference to the speed and success of commercialising these exciting new technologies.”
👉 Learn more: https://loom.ly/pUOUliw
CUREator+ is supported by funding from the Medical Research Future Fund (MRFF) BioMedTech Incubator (BMTI) program.
Related news
Dr Trang Nguyen29 September 2026C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic
C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic UPPSALA, Sweden/SYDNEY, Australia – September 29, 2026 – C-RAD (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.
Read more
Dr Sean Pollock17 September 2026ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy
SeeTreat co-founder Professor Paul Keall speaks with Sally Sara on innovating with radiotherapy. Prof Keall writes of this interview: "It was an honour to be invited to contribute to the ABC's Changing Australia series hosted by Sally Sara. On the question of how to bring innovations in radiotherapy to large numbers of patients I am proud that we at SeeTreat are doing just that: developing accessible technology to ensure that the radiation treatment is personalised to the patient throughout their course of therapy."
Read more
Antonia Dalton19 May 2026SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA
SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.
Read more